Browse IRF6

Summary
SymbolIRF6
Nameinterferon regulatory factor 6
Aliases OFC6; VWS; LPS; Van der Woude syndrome; PIT; PPS1; IRF-6
Chromosomal Location1q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Note=Translocates to nucleus in response to an activating signal.
Domain PF00605 Interferon regulatory factor transcription factor
PF10401 Interferon-regulatory factor 3
Function

Probable DNA-binding transcriptional activator. Key determinant of the keratinocyte proliferation-differentiation switch involved in appropriate epidermal development (By similarity). Plays a role in regulating mammary epithelial cell proliferation (By similarity). May regulate WDR65 transcription (By similarity).

> Gene Ontology
 
Biological Process GO:0007050 cell cycle arrest
GO:0008544 epidermis development
GO:0009913 epidermal cell differentiation
GO:0030216 keratinocyte differentiation
GO:0030879 mammary gland development
GO:0034340 response to type I interferon
GO:0034341 response to interferon-gamma
GO:0043588 skin development
GO:0043616 keratinocyte proliferation
GO:0045786 negative regulation of cell cycle
GO:0048732 gland development
GO:0050673 epithelial cell proliferation
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0060337 type I interferon signaling pathway
GO:0060644 mammary gland epithelial cell differentiation
GO:0061180 mammary gland epithelium development
GO:0071346 cellular response to interferon-gamma
GO:0071357 cellular response to type I interferon
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-913531: Interferon Signaling
R-HSA-909733: Interferon alpha/beta signaling
R-HSA-877300: Interferon gamma signaling
Summary
SymbolIRF6
Nameinterferon regulatory factor 6
Aliases OFC6; VWS; LPS; Van der Woude syndrome; PIT; PPS1; IRF-6
Chromosomal Location1q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IRF6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolIRF6
Nameinterferon regulatory factor 6
Aliases OFC6; VWS; LPS; Van der Woude syndrome; PIT; PPS1; IRF-6
Chromosomal Location1q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IRF6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIRF6
Nameinterferon regulatory factor 6
Aliases OFC6; VWS; LPS; Van der Woude syndrome; PIT; PPS1; IRF-6
Chromosomal Location1q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IRF6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.110.0446
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0370.968
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.9690.00601
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0230.962
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1660.929
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.160.944
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2680.773
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0840.949
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6220.661
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2030.843
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8560.517
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.350.06
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IRF6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIRF6
Nameinterferon regulatory factor 6
Aliases OFC6; VWS; LPS; Van der Woude syndrome; PIT; PPS1; IRF-6
Chromosomal Location1q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IRF6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIRF6
Nameinterferon regulatory factor 6
Aliases OFC6; VWS; LPS; Van der Woude syndrome; PIT; PPS1; IRF-6
Chromosomal Location1q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IRF6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IRF6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIRF6
Nameinterferon regulatory factor 6
Aliases OFC6; VWS; LPS; Van der Woude syndrome; PIT; PPS1; IRF-6
Chromosomal Location1q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IRF6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIRF6
Nameinterferon regulatory factor 6
Aliases OFC6; VWS; LPS; Van der Woude syndrome; PIT; PPS1; IRF-6
Chromosomal Location1q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IRF6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIRF6
Nameinterferon regulatory factor 6
Aliases OFC6; VWS; LPS; Van der Woude syndrome; PIT; PPS1; IRF-6
Chromosomal Location1q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IRF6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIRF6
Nameinterferon regulatory factor 6
Aliases OFC6; VWS; LPS; Van der Woude syndrome; PIT; PPS1; IRF-6
Chromosomal Location1q32.2-q32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IRF6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.